[1]徐卫皓,杨凤真,伊茂礼,等.临床耐碳青霉烯类肠杆菌科细菌对头孢他啶 /阿维巴坦的药物敏感性分析[J].现代检验医学杂志,2022,37(01):164-167.[doi:10.3969/j.issn.1671-7414.2022.01.033]
　XU Wei-hao,YANG Feng-zhen,YI Mao-li,et al.Drug Sensitivity Analysis of Clinical Carbapenem-resistant Enterobacteriaceae Bacteria to Ceftazidime/Avibatan[J].Journal of Modern Laboratory Medicine,2022,37(01):164-167.[doi:10.3969/j.issn.1671-7414.2022.01.033]
点击复制

临床耐碳青霉烯类肠杆菌科细菌对头孢他啶 /阿维巴坦的药物敏感性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年01期
页码:
164-167
栏目:
研究简报 实验技术
出版日期:
2022-01-15

文章信息/Info

Title:
Drug Sensitivity Analysis of Clinical Carbapenem-resistant Enterobacteriaceae Bacteria to Ceftazidime/Avibatan
文章编号:
1671-7414（2022）01-164-04
作者:
徐卫皓1; 2; 杨凤真2; 伊茂礼2; 薛兆平2; 王　鑫1; 张玉梅1
（1. 滨州医学院基础医学院病原生物学教研室，山东烟台 264000；2. 烟台毓璜顶医院检验中心，山东烟台 264000）
Author(s):
XU Wei-hao1; 2;  YANG Feng-zhen2;  YI Mao-li2;  XUE Zhao-ping2;  WANG Xin1; ZHANG Yu-mei1
（1. Department of Pathogen Biology, School of Basic Medicine, Binzhou Medical University, Shandong Yantai 264000,China; 2. Laboratory Center of Yantai Yuhuangding Hospital, Shandong Yantai 264000, China）
关键词:
耐碳青霉烯肠杆菌科细菌; 头孢他啶 /阿维巴坦; 药物敏感性试验; 碳青霉烯酶型检测
分类号:
R378.2；R446.5
DOI:
10.3969/j.issn.1671-7414.2022.01.033
文献标志码:
A
摘要:
目的　分析携带不同碳青霉烯酶的耐碳青霉烯类肠杆菌科细菌 (carbapenem-resistant Enterobacteriaceae，CRE)对头孢他啶 /阿维巴坦（ cerftazidime-avibactam，CZA）的药物敏感性，为临床合理精准用药提供依据。方法　采用药敏纸片扩散法（ K-B法）对烟台毓璜顶医院 2018～ 2020年临床分离并保存的 98株非重复 CRE菌株进行 CZA的药敏试验，并对 CZA抑菌圈在 20~22mm的菌株用微量肉汤稀释法 (broth microdilution method，BMD)进行验证，聚合酶链反应（ polymerase chain reaction，PCR）方法检测其碳青霉烯酶型，分析产不同碳青霉烯酶的 CRE菌株对 CZA的药物敏感性。结果　烟台毓璜顶医院 CRE菌株以产金属 β -内酰胺酶为主，占 72.45%，总体对 CZA敏感率为 23.47%。CZA对单产丝氨酸酶（ blaKPC，blaOXA-48）的 CRE敏感率为 100%，对单产金属酶（ blaNDM，blaVIM，blaIMP）的 CRE耐药率为 100%，对同时产丝氨酸酶和金属酶的 CRE菌株和对不产酶的 CRE菌株敏感率分别为 25.0%和 83.3%。结论　携带不同碳青霉烯酶的 CRE菌株对 CZA的药物敏感性不同， CZA体外药敏试验有必要在临床开展，同时需增加酶型检测方法指导临床精准用药。
Abstract:
Objective　To analyze the drug sensitivity of carbapenem-resistant Enterobacteriaceae (CRE) with differentcarbapenems to Cerftazidime-avibactam (CZA), and provide the basis for clinical rational and accurate drug use. Methods　Atotal of 98 non-repeat CRE strains isolated and preserved in Yantai Yuhuangding Hospital from 2018 to 2020 were tested forCZA drug susceptibility by K-B method, and a broth microdilution method (BMD) was used for strains with CZA inhibition zoneof 20~22mm, the polymerase chain reaction (PCR) method was used to detect the carbapenase type, and the sensitivity of CREstrains producing different carbapenases to CZA was analyzed. Results　In Yantai Yuhuangding Hospital, the CRE strain wasmainly metal-producing β -lactamase, accounting for 72.4%, and the sensitivity rate to CZA was 23.5%. CZA was 100% sensitiveto serinase (blaKPC, blaoxa-48), 100% resistant to metalase (blaNDM, blaVIM, blaIMP), and the sensitivity rates of CRE strains producingserinase and metalloenzyme and CRE strain not producing enzyme were 25.0% and 83.3%, respectively. Conclusion　CRE strainscarrying different carbapenases had different drug sensitivity to CZA, so it is necessary to carry out CZA drug sensitivity test invitro in clinic, and at the same time, enzyme type detection method should be added to guide clinical precision drug use.

参考文献/References:

[1] BANERJEE R, HUMPHRIES R. Clinical andlaboratory considerations for the rapid detection ofcarbapenem-resistant Enterobacteriaceae[J]. Virulence,2017, 8(4): 427-439.
[2] 张艳双, 刘静, 万楠, 等．耐碳青霉烯类肠杆菌科(CRE) 耐药分子机制及控制流行的应对策略[J]. 现代检验医学杂志,2019,34(2):1-4.ZHANG Yanshuang,LIU Jing,WAN Nan,et al.Molecular mechanism of carbapenem-resistantEnterobacteriaceae(CRE) resistance and copingstrategies for controlling epidemics [J]. Journal ofModern Laboratory Medicine,2019,34(2):1-4.
[3] SHIRLEY M. Ceftazidime-avibactam: A review inthe treatment of serious Gram-Negative bacterialinfections[J]. Drugs, 2018, 78(6): 675-692.
[4] 赵锦锦．头孢他啶- 阿维巴坦药品说明书[J]. 国外医药（抗生素分册）, 2019, 40(2):115-127.ZHAO Jinjin. Instruction of ceftazidime and avibactam[J]. World Notes on Antibiotics, 2019, 40(2):115-127.
[5] Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibilitytesting:30th edition CLSI supplement M100[S].Wayne：PA, CLSI M100,2020.
[6] SUAY-GARC?A B,P?REZ-GRACIAMT P. Presentand future of carbapenem-resistant Enterobacteriaceae(CRE)infections[J]. Antibiotics (Basel, Switzerland),2019, 8(3): 122.
[7] HAN Renru, SHI Qingyu, WU Shi, et al. Disseminationof carbapenemases (KPC, NDM, OXA-48, IMP,and VIM) among carbapenem-resistant Enterobacteriaceaeisolated from adult and children patients in China[J]. Front Cell Infect Microbiol. 2020, 10:314.
[8] 胡付品, 郭燕, 朱德妹, 等．2018 年CHINET 中国细菌耐药性监测[J]．中国感染与化疗杂志, 2020,20(1):1-10.HU Fupin, GUO Yan, ZHU Demei,et al. CHINETsurveillance of bacterial resistance in China:2018 report[J]. Chinese Journal of Infection andChemotherapy, 2020,20(1):1-10.
[9] 张敬霞, 贾天野, 张树永, 等．头孢他啶/ 阿维巴坦对耐碳青霉烯肠杆菌科细菌的体外抗菌活性研究[J]. 中国抗生素杂志, 2018,43(9):1109-1116.ZHANG Jingxia,JIA Tianye, ZHANG Shuyong,etal. Study on in vitro antimicrobial activities ofceftazidime/avibactam to carbapenem-resistantEnterobacteriaceae[J].Chinese Journal of Antibiotics,2018,43(9):1109-1116.
[10] WANG Qi, ZHANG Feifei, WANG Zhanwei, et al.Evaluation of the E-test and disk diffusion methodfor detection of the activity of ceftazidime-avibactamagainst Enterobacterales and Pseudomonas aeruginosain China [J]. BMC Microbiology, 2020, 20(1): 187.
[11] SADER H S, RHOMBERG P R, CHANDRASEKARANS, et al. Correlation between broth microdilutionand disk diffusion results when testingceftazidime-avibactam against a challenge collectionof Enterobacterales isolates: results from a multilaboratorystudy[J]. Journal of Clinical Microbiology, 2020,58(4): e01719-e01757.

备注/Memo

备注/Memo:
基金项目：山东省医药卫生科技发展计划项目（202011001140）。
作者简介：徐卫皓（1987-），女，本科，主管检验师，研究方向：病原微生物学。
通讯作者：张玉梅（1981-），女，博士，副教授，研究方向：病原微生物学，E-mail:meiyuzh@163.com。
更新日期/Last Update: 1900-01-01